

Using quantitative magnetic resonance imaging to track cerebral alterations in multiple sclerosis brain: a longitudinal study

Nora Vandeleene^a, Camille Guillemain^{a,b}, Solène Dauby^{a,c}, Florence Requier^{a,b}, Maëlle Charonitis^{a,b}, Daphne Chylinski^{a,b}, Evelyne Balteau^a, Pierre Maquet^{a,c}, Emilie Lommers^{a,c*}, Christophe Phillips^{a,d*}

^a GIGA CRC in vivo Imaging, University of Liège, Liège, Belgium

^b Psychology and Cognitive Neuroscience Research Unit, University of Liège, Liège, Belgium

^c Clinical Neuroimmunology Unit, Neurology Department, CHU Liège, Belgium

^d GIGA in silico Medicine, University of Liège, Liège, Belgium

* These authors equally contributed to the work.

Corresponding author: Christophe PHILLIPS
GIGA – CRC in vivo imaging B30
Allée du 6 août
4000 Liège
Belgium

Acknowledgements

The authors are particularly thankful for the patients who took part in this study. N.V., E.L. and C.P. are supported by the Fonds de la Recherche Scientifique (F.R.S-FNRS Belgium).

Data availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Conflict interests

None.

Abbreviations:

ARoC: Annual Rate of Change, **BPF:** Brain Parenchymal Fraction, **CDP:** Confirmed Disability Progression, **cmMRI:** Conventional Magnetic Resonance Imaging, **CNS:** Central

39 Nervous System, **GMF**: Grey Matter Fraction, **GLMM**: General Linear Mixed Model, **LF**:
40 Lesion Fraction, **MPM**: Multi-Parameter Mapping, **MRI**: Magnetic Resonance Imaging,
41 **MS**: Multiple Sclerosis, **MT**: Magnetization Transfer, **MTR**: Magnetization Transfer
42 Ratio, **MTsat**: Saturated Magnetization Transfer, **NABT**: Normal Appearing Brain
43 Tissue, **NACGM**: Normal Appearing Cortical Grey Matter, **NADGM**: Normal Appearing
44 Deep Grey matter, **NAWM**: Normal Appearing White Matter, **NEDA-3**: No Evidence of
45 Disease Activity, **RRMS**: Relapsing-Remitting Multiple Sclerosis, **PD**: Proton Density,
46 **PMS**: Progressive Multiple Sclerosis, **qMRI**: Quantitative Magnetic Resonance Imaging,
47 **R1**: Longitudinal Relaxation Rate ($1/T1$), **R2***: Transverse Relaxation Rate ($1/T2^*$), **TIV**:
48 Total Intracranial Volume, **TPM**: Tissue Probability Map, **US**: Unified Segmentation,
49 **USwL**: Unified Segmentation with Lesion

50 **Abstract**

51 Quantitative MRI quantifies tissue microstructural properties and supports the
52 characterization of cerebral tissue damages. With an MPM protocol, 4 parameter maps
53 are constructed: MTsat, PD, R1 and R2*, reflecting tissue physical properties
54 associated with iron and myelin contents. Thus, qMRI is a good candidate for *in vivo*
55 monitoring of cerebral damage and repair mechanisms related to MS. Here, we used
56 qMRI to investigate the longitudinal microstructural changes in MS brain.

57 Seventeen MS patients (age 25-65, 11 RRMS) were scanned on a 3T MRI, in two
58 sessions separated with a median of 30 months, and the parameters evolution was
59 evaluated within several tissue classes: NAWM, NACGM and NADGM, as well as focal
60 WM lesions. An individual annual rate of change for each qMRI parameter was
61 computed, and its correlation to clinical status was evaluated. For WM plaques, three
62 areas were defined, and a GLMM tested the effect of area, time points, and their
63 interaction on each median qMRI parameter value.

64 Patients with a better clinical evolution, i.e., clinically stable or improving state,
65 showed positive annual rate of change in MTsat and R2* within NAWM and NACGM,
66 suggesting repair mechanisms in terms of increased myelin content and/or axonal
67 density as well as edema/inflammation resorption. When examining WM lesions, qMRI
68 parameters within surrounding NAWM showed microstructural modifications, even
69 before any focal lesion is visible on conventional FLAIR MRI.

70 The results illustrate the benefit of multiple qMRI data in monitoring subtle changes
71 within normal appearing brain tissues and plaque dynamics in relation with tissue
72 repair or disease progression.

73

74 Keywords:

75 Quantitative MRI, relaxometry, longitudinal analysis, multiple sclerosis.

76

77 Key points:

78 • Patients with a better clinical evolution showed microstructural improvement
79 in term of MTsat and R2* increase in their normal appearing tissue, suggesting
80 repair mechanisms.

81 • Using qMRI allows to detect modifications in tissue microstructure in normal
82 appearing tissues surrounding lesions several months before they are visible on
83 conventional MRI.

84

85

86 **1. Introduction**

87 Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS).

88 Plaques are the pathological hallmark of MS. They are spread in acute, focal, disseminated
89 and recurrent way throughout the CNS and harbor variable degrees of inflammation,
90 demyelination, gliosis and axonal injury [1, 2]. Plaques are not restricted to the white matter
91 (WM), but are also present in the cortex and deep grey matter (GM) [3-5].

92 Over and above focal WM lesions, an early, diffuse and chronic inflammation within the
93 normal appearing white matter (NAWM) and grey matter (NAGM) is ultimately responsible
94 for diffuse neuro-axonal loss and neurodegeneration, which is deemed responsible for a
95 progressive accumulation of disability [3, 4, 6].

96 By contrast, effective repair mechanisms can occur within focal lesions but probably also in
97 normal appearing brain tissue (NABT) [7]. However, our understanding of these complex
98 processes is still fragmentary. The difficulty of acquiring histopathological data on MS patients
99 at various stages of the disease makes it challenging to describe the time course of injury and
100 potential repair mechanisms in MS. Consequently, there is a need for new imaging techniques
101 to improve the *in-vivo* monitoring of brain damages formation, progression and repair in MS
102 [8].

103 Conventional MRI (cMRI) readily depicts focal WM lesions on T2/FLAIR sequences and is able
104 to distinguish between acute and allegedly chronic lesions. T2-hyperintensities in cMRI
105 constitute the keystone of McDonald diagnostic criteria [9] and also make an important
106 contribution to the monitoring of WM lesion burden. Unfortunately, cMRI sequences do not
107 sensitively detect cortical lesions and diffuse changes in NABT, due to a rather low sensitivity
108 of cMR imaging for cortical lesions, mixed contrast weight, and an overall limited
109 histopathological specificity within cerebral tissues. Quantitative MRI (qMRI) potentially

110 overcomes these limitations by quantifying physical microstructural properties of cerebral
111 tissue in standardized units. qMRI is more sensitive but also more specific to microstructural
112 properties of CNS tissues. Magnetization transfer ratio (MTR) was regularly linked to cerebral
113 macromolecular content detected by a greater percentage loss of magnetization in voxels with
114 a higher myelin content and axons density [10-12]. Post-mortem studies comparing the
115 relative contribution of these two factors indicate that myelin has a stronger and more direct
116 influence on MTR than the axonal density, which is considered as a T1-dependent effect.
117 Tissue water content (inflammation, edema...), another T1-dependent effect, also accounts
118 for MTR variability [11, 13, 14]. However, the MT saturation (MTsat) map offers a measure
119 which, unlike MTR, is minimally affected by longitudinal relaxation and B1 mapping
120 inhomogeneities [15], increasing its sensitivity to myelin content. Moreover, the brain
121 contrast to noise ratio is larger for the MTsat map than for MTR, thus improving brain tissue
122 segmentation in healthy subjects [11, 16]. $R2^*$ was usually linked to iron and myelin contents,
123 as paramagnetic iron and diamagnetic myelin generate microscopic field gradients in the CNS,
124 thus shortening $T2^*$ and increasing $R2^*$ ($1/T2^*$). Orientation and density of myelin fibers are
125 also a determining factor of $R2^*$ values [17-19]. Iron is probably a key factor in MS monitoring
126 as it was shown that aberrant iron metabolism occurs in the course of the disease [20].
127 Particularly increased iron concentration within chronic active lesions (i.e iron rim lesion) or
128 deep grey matter structures was observed [20]. Regarding the longitudinal relaxation rate $R1$
129 ($1/T1$), its three major determinants in the CNS are tissue myelination and associated axons,
130 iron, and extracellular water contents [19, 21, 22]. Finally, proton density (PD) mostly reflects
131 the free water content of the brain [23].

132 A number of cross-sectional studies using a combination of MT, $R1$, $R2^*$ or PD parameters,
133 comparing MS patients to healthy controls, reported significant changes in the microstructure

134 of NABT, such as a decrease in MT, R1 and R2* and an increase in PD in patients [24-32]. Few
135 studies addresses the longitudinal variations in qMRI. R2* [33-35], PD and T1 were reported
136 to increase in the basal ganglia over a period of a year [36], whereas a decrease in MTR in
137 NAWM was reported over one [37] or two years [38].

138 Regarding focal WM plaques, qMRI emerges as an appealing biomarker to describe the
139 dynamic processes of demyelination and remyelination. For instance, MTR was shown to
140 sharply decrease within gadolinium enhancing lesions before recovering during the
141 subsequent months [39-41], and within NAWM days to weeks before the formation of a new
142 active lesion [42, 43].

143 Because each qMRI parameter is differently sensitive to histologically measured iron and
144 myelin contents, this approach might become a fundamental tool for longitudinal *in vivo*
145 monitoring of MS lesions and NABT evolution at the tissue microstructural level.

146 In this longitudinal study, we investigate the evolution of four simultaneously acquired qMRI
147 parameters (MTsat, PD, R1, R2*) within NABT and WM lesions of 17 MS patients - relapsing
148 remitting (RRMS) and progressive MS (PMS) - who were scanned two times with at least a
149 one-year interval, following the same multi-parameter mapping (MPM) protocol at 3 Tesla
150 [10, 44].

151 We assessed the time course of parameter values in several tissue classes: normal appearing
152 white matter (NAWM), normal appearing cortical and deep GM (NACGM and NADGM) as well
153 as focal WM lesions. In addition, we related longitudinal qMRI changes within NABT to clinical
154 course.

155 **2. Materials and methods**

156 **2.1 Population**

157 Seventeen patients, recruited at the specialized MS outpatient clinic of the CHU Liège,
158 Belgium, with a diagnosis of MS according to the McDonald criteria 2010 [45], were gathered
159 from two studies: ten of them were part of the work reported by Lommers et al. 2019 [24],
160 the other seven were recruited from another MS study taking place at the GIGA Cyclotron
161 Research Centre – In Vivo Imaging (Liège, Belgium) [46]. For the first study (10 subjects), the
162 inclusion criteria were (1) age between 18 and 65 years ; (2) Expanded Disability Status Scale
163 (EDSS) inferior or equal to 6.5 ; (3) absence of relapse within the previous four weeks ; (4)
164 absence of IVMP administration for at least 6 months prior to the study. Both RRMS and PMS
165 patients were recruited. The second study (7 subjects) differs a bit as it comprises only RRMS
166 patients, and the inclusion criteria were (1) age between 18 and 45, (2) EDSS between 0 and
167 4, (3) absence of relapse for at least 6 months prior to the study, (4) disease duration was
168 below or equal to 5 years, (5) absence of IVMP administration for at least 6 months prior to
169 the study. For both studies, compatibility with MRI and absence of other
170 neurological/psychiatric diseases were required. These studies were approved by the local
171 ethics committee (approval numbers B707201213806 and B707201835630, respectively). All
172 patients were followed up and scanned twice on the same 3T MRI scanner, every 1 to 3 years.
173 For each of the 17 MS patients, data from two MRI sessions were available, at T0 and T1. This
174 cohort included 11 RRMS and 6 (primary and secondary) PMS patients. Thirteen were
175 receiving disease-modifying treatments (DMTs). The patients' median age was 36 years
176 (range: 25-65) and the median time interval between two scans was 30 months (range: 14-
177 61). Demographic data appears in Table 1. Extended individual information appears in
178 Supplementary data.

179

180

2.2 MR image acquisition

181 MRI data were acquired on a 3T whole-body MRI-scanner (Magnetom Prisma, Siemens

182 Medical Solutions, Erlangen, Germany). The whole-brain MRI acquisitions included a multi-

183 parameter mapping protocol (MPM), from which one can simultaneously estimate

184 (semi)quantitative maps of magnetization transfer saturation (MTsat), proton density (PD),

185 transverse relaxation (R1) and effective longitudinal relaxation (R2*). This protocol arising

186 from an international collaborative effort [10, 44], has already been used to study brain

187 microstructure in various conditions including normal aging [9, 44, 47], brain tumor [48],

188 Parkinson's disease [49-51] as well as MS. It consists of three co-localized 3D multi-echo fast

189 low angle shot (FLASH) acquisitions at 1mm³ resolution and two additional calibration

190 sequences to correct for inhomogeneities in the RF transmit field [52, 53]. The FLASH datasets

191 were acquired with predominantly PD, T1 and MT weighting, referred to in the following as

192 PDw, T1w and MTw, at multiple echo times. All three had high bandwidth to minimize off-

193 resonance and chemical shift artifacts. Volumes were acquired in 176 sagittal slices using a

194 256x224 voxel matrix. GRAPPA parallel imaging was combined with partial Fourier acquisition

195 to speed up acquisition time to approximately 20 min. An additional FLAIR sequence was

196 recorded with spatial resolution 1mm³ and TR/TE/TI=5000ms/516ms/1800ms. Extra B1 field

197 mapping images (transmit B1+ and receive B1- fields) were also acquired to reduce spatial

198 inhomogeneities related to B1 effect. This was essential for proper quantification of T1 (or

199 $R1=1/T1$) in particular. Finally, B0 field mapping images, corresponding to both magnitude

200 images and pre-subtracted phase image, were acquired for image distortions corrections. A

201 summary of the acquisition parameters appears in Supplementary data.

202 Note that these MR sequences at 3 Tesla are not sensitive to cortical lesion as described in
203 [54, 55] although a few lesions at the cortico-subcortical border were detected. Quantification
204 of cortical parameters is thus confounded by voxels potentially located within cortical lesions.

205 **2.3 MR image processing**

206 All data processing was performed in Matlab (The MathWorks Inc., Natick, MA, USA) using
207 SPM12 (www.fil.ion.ucl.ac.uk/spm) and three additional dedicated SPM extensions: the
208 Lesion Segmentation Tool (LST) version 1.2.3 (www.statisticalmodelling.de/lst.html) [56], the
209 “quantitative MRI and in vivo histology using MRI” toolbox (hMRI, <http://hmri.info>) [10], and
210 “US-with-Lesion” tool (USwL, <https://github.com/CyclotronResearchCentre/USwLesion>).

211 Quantitative maps - MTsat, PD, R1 and R2* - were estimated using the hMRI toolbox. T1w,
212 PDw and MTw images acquired at multiple echo times (TE) were extrapolated to TE=0 to
213 increase signal-to-noise ratio and remove the otherwise remaining R2* bias [10, 24, 57]. The
214 TE=0 extrapolated MTw, PDw and T1w images were used to calculate MT saturation, R1 and
215 apparent signal amplitude A* maps. PD map was derived from A* map, which is proportional
216 to proton density. All quantitative maps were corrected for inhomogeneities from local RF
217 transmit field (B1+), and R1 quantitative maps were further corrected for imperfect RF spoiling
218 using the strategy of Preibisch and Deichmann [58]. The receive bias field map (B1-) was used
219 to correct PD maps for instrumental biases. The R2* map was estimated from all three multi-
220 echo series (MTw, PDw and R1w) using the ESTATICS model [57].

221 After generating quantitative maps using the hMRI toolbox for all sessions, spatial
222 preprocessing involved the following steps (Figure 1): within-patient registration brought the
223 two serial MR data sets into the individual T0 space, using the longitudinal registration tool
224 from SPM [59]. For each individual patient, a preliminary WM lesion mask was generated
225 based on FLAIR and T1w images by the lesion growth algorithm implemented in the LST

226 toolbox [56], followed by manual corrections by an MS expert (EL) to remove
227 aberrant/artefactual lesion detections [24]. The images were then segmented using the USwL
228 toolbox, which consists of an extended version of the traditional Unified Segmentation (US)
229 algorithm [60] and includes an additional tissue class representing the WM lesion(s). The US-
230 with-lesion method internally generates a subject-specific extended set of tissue probability
231 maps (TPM) [61]: an extra tissue class, based on the smoothed preliminary lesion mask warped
232 into template space (using cost function masking during normalization [62]), is added to
233 account for the lesion, and the original white matter prior map is updated accordingly [63].
234 The grey matter TPM was not updated due to a very low number of lesions present in the
235 cortical ribbon. Multi-channel segmentation was conducted, using MTsat, PD, R1 and FLAIR
236 images. This pipeline did not use the PD-, T1- and MT-weighted images acquired for the MPM
237 maps construction, but the parametric maps themselves instead. In this way, voxels do not
238 depict MR intensities but rather physical quantitative parameters. The method generated the
239 segmented tissue classes (*a posteriori* tissue, including lesion, probability maps), as well as
240 spatial warping into standard template space. The preliminary lesion mask was used as input
241 for the first session data (at T0) then the *a posteriori* lesion map generated at this initial step
242 served as prior to the subsequent session (at T1).

243 Segmentation teased out the different tissue classes of interest: NAWM, NACGM and NADGM,
244 as well as WM lesions. To analyze the microstructure within those tissue classes, *a posteriori*
245 tissue maps were binarized and tissue-specific independent masks were constructed: each
246 voxel is assigned to one single tissue class with the highest probability for that voxel (provided
247 that this probability was above 0.2). The lesion binary mask was further cleaned for lesions
248 <10mm³ which likely resulted from segmentation errors. Finally, binarized tissue class masks
249 were in turn applied on the MPM maps to extract voxel values inside them.

250 **2.4 Brain volume change**

251 Volumetric changes were investigated using the USwL *a posteriori* tissue probability maps. The
252 following measures of brain volume were computed for each session of each participant: (1)
253 Total intra-cranial volume (TIV) = volume (NAWM + GM + CSF + lesions), (2) brain parenchymal
254 fraction (BPF) = volume (NAWM + GM + lesions)/TIV, (3) Gray matter fraction (GMF) = volume
255 (GM)/TIV, and (4) lesion fraction (LF) = volume (lesion)/TIV. The percentage of change
256 between both scanning sessions was evaluated for each volumetric measurement, then
257 annualized changes were computed by dividing these measures by scan intervals (in years).
258 Results were directly analysed with a t-test (testing if significantly different from 0 at $p < .05$),
259 but also in the same way as the normal appearing tissues MR parameters in relation to the
260 patients' clinical status (see next section).

261 **2.5 Analysis of normal appearing tissues**

262 The median value of quantitative MRI parameters was extracted from the three normal
263 appearing tissues (NAWM, NACGM and NADGM), and an individual annual rate of change
264 (ARoC) was computed for each parameter in each tissue class, based on the initial and final
265 values and accounting for the time interval (in years) between scans. This rate of change in
266 qMRI parameters served as dependent variable in a general linear model testing the effect of
267 clinical status:

$$268 \qquad Y = \beta_0 + \beta_1 X_{status} + \epsilon$$

269
270 Y is the ARoC for a qMRI parameter and tissue class, β 's are the regression parameters
271 corresponding to the associated regressor (with β_0 the intercept), and ϵ the residuals. X_{status}
272 is a binary categorical variable representing the patient's disease activity status: a status score
273 of 1 was assigned to patients stable or improving from T0 to T1.

274 This patient status X_{status} was derived from one score of disease activity: NEDA-3 (No
275 Evidence of Disease Activity [64]), a composite of three related measures of disease activity.
276 A score of 0 was assigned in the presence of new clinical relapses (only concerning RRMS
277 patients) and/or MRI activity (new or enlarged lesions visible on FLAIR T2 or Gadolinium-
278 enhanced images) and/or sustained disability progression over six months based on Expanded
279 Disability Status Scale (EDSS). For both RRMS and PMS patients, disability progression was
280 defined as a 1.0-point increase if the EDSS score was ≤ 4.0 at baseline and as a 0.5 point
281 increased if the baseline EDSS score was > 4.0 . The threshold of 4.0 was proposed in this study
282 because it is considered as a milestone regarding ambulatory performance.

283 NEDA-3 and was evaluated at mid- and end-scanning interval, and a final status score of 0 was
284 given only to patients for which disease activity or progression was noted in both cases,
285 indicating a clear progression of the disease over the whole interscan interval.

286 The influence of several clinical measurements such as 25 FWT, 9HPT and SDMT was also
287 considered to refine the evaluation of disease activity. However complete data were lacking
288 for several patients. Moreover, when available, these additional clinical parameters did not
289 modify the final X_{status} . Longitudinal clinical information allowing to derive the disease
290 activity status for each subject appears in Table 2. Additional clinical information concerning
291 annual relapse rate and treatment administration appears in Supplementary material.

292 Permutation tests were employed for inferences [65]. R-squared value was tested against
293 computed statistics after permutation of the data. For a number n of permutations, the
294 X_{status} values were randomly shuffled (constructing a new regressor written X_{status}^{π}), tested
295 against the unchanged response Y , and generating each time a permuted R-squared value
296 (noted R_{π} , R_{obs} being the true R-squared value computed without permutation of the data).

297 The condition $X_{status} \neq X_{status}^{\pi}$ is verified at each permutation. After n permutations (with n
298 = 5000 in this study), a p -value was computed based on the following formula:

$$299 \quad p = \frac{\#(R_{\pi} > R_{obs})}{n + 1}$$

300 which estimates the probability of obtaining R_{obs} under the null hypothesis that Y is not
301 correlated to X_{status} . The null hypothesis is rejected if $p < .05$ FDR-corrected for multiple
302 comparisons [66], for the 12 tests performed (3 tissue classes with 4 qMRI parameters).

303 Two-tailed t-tests were applied *post-hoc* on the significant results of permutation tests to
304 compare the AROC distribution between disease status, i.e., $X_{status} = 0$ against $X_{status} = 1$.

305 Inferences were conducted at a significance level of .05.

306 The same pipeline was applied to the brain volumetric changes (BPF, GMF and LF) to test their
307 correlation to the disease activity status.

308 **2.6 Analysis of lesions and peripheral tissues**

309 For white matter lesions analysis, we did not use AROC but exploited directly the qMRI
310 parameters voxel values. Importantly, with USwL segmentation, the prior lesion mask is only
311 used in a probabilistic way and the estimated posterior lesion map, obtained using MTsat, PD,
312 R1 and FLAIR images, typically showed more extended lesion than clinically visible on the
313 FLAIR image alone. Therefore, we separated focal lesions detected on FLAIR images, with LST
314 segmentation and visual inspection, from their peripheral regions detected on qMRI maps.
315 Two different peripheral regions were considered: one for each time point (T0 and T1).
316 Therefore, at T0, three distinct lesion-related regions were isolated:

- 317 • The lesions, as clinically defined, pertaining to hyperintensity on the conventional FLAIR
318 MR image acquired at T0. These are referred to as ‘focal FLAIR lesion’.
- 319 • The peripheral region detected on qMRI maps at T0, at the borders of (but not including)
320 the focal FLAIR lesion. Those are referred to as ‘initial peripheral lesion’.

321 • The peripheral region, detected on qMRI maps at follow up, bordering (but not including)
322 the initial peripheral lesion, further referred to as 'later peripheral lesion'. This was
323 computed by masking out the T1 lesion mask with the T0 lesion mask. This region allows
324 us to determine whether its microstructure at T0 forebodes a full-blown plaque,
325 detectable during follow up. Those sometimes appear hyperintense on FLAIR images.

326 The three areas were compared between each other and with NAWM, in order to characterize
327 them on a microstructural basis (Figure 2). For an accurate lesion-by-lesion analysis, only
328 enlarging lesions, i.e., present in the three masks, were considered for these comparisons.

329 NAWM region consisted of all white matter voxels which did not belong to any of the three
330 lesion-related regions. The four areas are not overlapping as no voxel could belong to more
331 than one class at the same time.

332 For all participants, MTsat, PD, R1 and R2* median values were extracted from each lesion
333 area, considering lesions individually (between 2 and 66 measurements per subject). Similarly,
334 the median qMRI values within NAWM were also extracted (one measurement per subject).
335 These values were extracted from T0 and T1 scans separately. Statistical analyses were
336 performed in SAS 9.4 (SAS Institute, Cary, NC). None of the qMRI parameter was normally
337 distributed, therefore we applied a log transformation on each of them prior to statistical
338 analysis. For each qMRI parameter, a separate Generalized Linear Mixed Model (GLMM)
339 tested the effect of areas (NAWM and the three lesion-related areas), and time points (T0 and
340 T1), as well as their interaction (i.e., area*time), on the median qMRI parameter value, with a
341 first-order autoregressive variance/covariance model and participants as a random factor
342 (intercept). The degrees of freedom were estimated using Kenward-Roger's method.
343 Statistical significance was estimated at $p < .05$ after adjustment for multiple comparison
344 using Tukey's procedure.

345 **3. Results**

346 **3.1 Volume changes**

347 Brain parenchymal fraction (BPF) annually decreased between T0 and T1 by $-0.67 \pm 1.12\%$
348 (significantly different from zero; paired-sample t-tests; $t(16) = 2.57; p = .0204$) whereas
349 lesion fraction (LF) increased by $22.88 \pm 26.13\%$ ($t(16) = -3.70; p = .0019$). GM fraction
350 (GMF) non-significantly decreased by $-0.30 \pm 1.44\%$.

351 **3.2 Analysis of normal appearing tissues**

352 As expected, changes in MTsat and R2* within normal appearing brain tissues (NABT) between
353 T0 and T1 varied across subjects (Figure 3). PD and R1 exhibited similar behaviors, see
354 Supplementary data.

355 At the group level, with the regression analysis and permutation inference, we observed that
356 the annual rate of change (ARoC) of MTsat and R2* positively regressed with disease status as
357 follows (Table 3): MTsat in NAWM and NACGM and R2* in NAWM significantly increased in
358 patients who fare well ($X_{status} = 1$).

359 *Post-hoc* t-tests applied on these significant results for a clearer illustration of the difference
360 in disease status (Figure 4) were all significant at a level of .05.

361 Regarding BPF and LF, their correlation to the disease activity status was not significant (Table
362 3), suggesting that qMRI parameters are more sensitive to subtle microstructural changes in
363 normal appearing tissues over time than global morphological measurements

364 **3.3 Analysis of lesion microstructure**

365 The number of enlarging WM lesions between T0 and T1 varied from 2 to 66 across patients,
366 for a total of 741 identified enlarging lesions among all subject, corresponding on average
367 among patients to 63% ($\pm 31\%$) of the amount of initial focal lesions. The number of enlarging

368 lesions did not significantly differ between patients' disease status groups ($t(15) = .244, p =$
369 $.811$).

370 GLMMs found a significant effect of areas (3 lesion regions and NAWM) for MTsat, R1, R2*
371 and PD median (MTsat: $F_3 = 35.34, p < .0001$, PD: $F_3 = 68.03, p < .0001$, R1: $F_3 =$
372 $40.26, p < .0001$, R2*: $F_3 = 32.32, p < .0001$). By contrast, neither time effect (T0 vs T1;
373 MTsat: $F_3 = 0.36, p = .5481$, PD: $F_3 = 1.20, p = .2735$, R1: $F_3 = 2.05, p = .1520$, R2*:
374 $F_3 = 2.86, p = .0911$), nor the area*time interaction (MTsat: $F_3 = 0.09, p = .9671$, PD:
375 $F_3 = 0.14, p = .9346$, R1: $F_3 = 0.14, p = .9331$, R2*: $F_3 = 0.40, p = .7565$) were
376 significant, suggesting the microstructural stability of the initial lesion core. *Post-hoc* tests
377 confirmed significant differences between the four tissue areas.

378 At times T0 and T1, MTsat, R1 and R2* values were significantly larger in the initial peripheral
379 lesion than FLAIR lesion, in the later peripheral lesion than the initial one, and in the NAWM
380 than later peripheral lesion. The reverse was observed for PD. The significant difference in
381 parameters between initial and later peripheral lesion at T0 suggests that subtle
382 microstructural changes appear in the periphery of the initial lesion, months before their
383 detection as focal FLAIR lesions at T1. Adjusted p -values appear in Figure 5. Detailed statistical
384 results of the GLMM's appear in Supplementary data.

385 **4. Discussion**

386 This longitudinal study followed up volumetric data and qMRI brain metrics (MTsat, PD, R1,
387 R2*) in 17 patients with multiple sclerosis for a median time interval of 30 months. The main
388 results are threefold. First, the microstructure of normal appearing brain tissues changes over
389 time and these modifications concur with, and potentially drive, clinical evolution. This critical
390 finding suggests that repair mechanism and edema resorption can be monitored *in vivo*.
391 Second, the microstructure within WM plaques is remarkably heterogeneous. Importantly, at

392 their periphery, microstructural alterations foreshadow their expansion, as detected by
393 conventional MRI. Third, as expected, we observed a small but significant brain atrophy and
394 lesion load increase with time.

395 **Quantitative MRI parameter time course within NABT**

396 In this study, we used a multiparameter mapping protocol that was gradually optimized and
397 validated for multi-centric studies [67]. It provides high-resolution maps of multiple qMRI
398 parameters from data acquired during a single scanning session of acceptable duration. A
399 number of cross-sectional studies using a combination of MT, R1, R2* or PD parameters
400 reported significant changes in the microstructure of NABT in MS [24-32]. By contrast,
401 longitudinal analyses of multiparameter qMRI data are scarce. A progressive shortening of
402 T2/T2* [68] or increase in R2* [33-35] was reported within the basal ganglia, suggesting
403 increased of myelin and/or iron contents as well as edema resorption. Likewise, PD and T1
404 increased within a year, suggesting a demyelination and/or axonal loss [36]. MTR progressively
405 decreases in NAWM of MS patients over one [37] or two years [38]. These abnormalities tend
406 to be more pronounced in progressive phenotypes [69] and were associated to a slow, diffuse
407 and global myelin pathology.

408 Here, we showed that MTsat within NAWM and NACGM and R2* values within NAWM
409 increase in clinically stable or improving patients. Because MTsat and R2* both correlate with
410 myelin content [11, 47, 70-73], our results suggest repair mechanisms within NABT of patients
411 who are responding to disease modifying treatments, despite the initial myelin/axonal loss
412 and independently from WM focal lesion evolution. Such increases could also be explained by
413 an edema/inflammation resorption, but less likely than myelin/axonal density changes since
414 MTsat is the least dependent to water content among the four qMRI parameters. These
415 results echo cross-sectional analyses showing that healthy controls (HC) have higher MTsat

416 and R2* values within the same tissue classes compared to MS patients [24]. Annual rates of
417 change of R1 and PD within NABT were not significantly associated with the individual clinical
418 status in this study, although R1 reduction within NABT has already been reported in cross
419 sectional [24, 29, 30] and longitudinal [36] studies comparing MS subjects to HC.

420 **Lesion microstructure**

421 Focal inflammatory demyelinating lesions have been extensively characterized and are
422 traditionally classified as active, chronic active (smoldering) or inactive plaques according to
423 the presence and distribution of plaque-infiltrating macrophages/microglia [74-76]]. Focal
424 WM pathology is a constantly evolving process including episodes of demyelination and
425 remyelination but also accumulation of irreversible axonal damage. Age, disease duration,
426 clinical phenotype as well as disease modifying treatment all contribute to the dynamic nature
427 of focal WM pathology [75, 77]. This accounts for the large inter- and intra-individual
428 heterogeneity of MS, which conventional MRI is largely unable to capture. By contrast,
429 quantitative MRI parameters are sensitive to myelin, axonal as well as iron contents and
430 appear as promising markers of plaque dynamics. For instance, MTR was shown to sharply
431 decrease within gadolinium enhancing lesions before recovering during the subsequent
432 months [39-41]. Likewise, reduction of MTR within NAWM, days to weeks before the
433 formation of a new active lesion was also demonstrated [42, 43], and long-term MTR changes
434 in WM plaques were observed in relation with disease progression [69, 78]. The present study
435 broadens the quantitative characterization of plaque dynamics, in keeping with previous
436 longitudinal studies [68, 79]. Two important findings emerge from the results. First, qMRI
437 refines lesion segmentation, as compared to the processing based on the sole FLAIR image. In
438 consequence, the initial lesion revealed by qMRI is typically wider than the plaque detected in
439 FLAIR. Its periphery is characterized by a decrease in MTsat and R2* as compared to NAWM,

440 suggesting an incipient demyelination, reminiscent of the so-called ‘periplaques’ [80].
441 Moreover, MTsat, R2* and R1 values progressively decrease from NAWM to plaque core,
442 suggesting a centripetal loss of myelin content. Second, plaque microstructure is altered in
443 plaque periphery before any observable change in conventional MRI signals. This finding
444 suggests, in keeping with neuropathological observations [75, 77, 81, 82] that subclinical
445 ongoing inflammation and/or demyelination takes place in the periphery of an active plaque,
446 well before it is detectable on FLAIR or T1 post-gadolinium sequences. If confirmed on larger
447 population samples, this finding might significantly modify treatment management in MS
448 patients.

449 Another plausible hypothesis explaining the progressive decrease of R2* in initial and later
450 peripheral regions is that iron-containing macrophages could be removing iron from the
451 lesions through perivascular drainage into the extracellular compartment. Previous
452 neuropathological studies have reported an iron loss at the edges of a subset of MS lesions,
453 depending on their type (active, inactive, smoldering, etc.) as well as the patient’s age and
454 disease duration [83, 84]. Due to the limited sensitivity of R2* to local iron concentration as
455 compared, for example, to the combined use of R2* and quantitative susceptibility mapping
456 (QSM) [18], validating this theory would require additional measures which can better
457 describe iron dynamics in MS lesions and NAWM.

458 **Volumetric Data**

459 CNS atrophy occurs in all stages of MS, since the preclinical phase of the disease and
460 progresses throughout its course, at a much higher rate than one reported in normal aging
461 [85-88]. In this study, the annual brain percentage volume loss at the group level was 0.67%,
462 which is in line with previous publications [89]. We also showed a significant increase in lesion
463 fraction. Volumetric data (ARoC’s) were highly variable across subjects: changes in BPF range

464 from -2.52 to 1.17% and LF from -0.78 to 103.06%. This variability arises from a large number
465 of factors which do not necessarily relate to MS: age, disease duration, disease phenotype,
466 disease modifying treatment, circadian rhythm, hydration... [87, 88].
467 Moreover, annual changes in brain parenchymal fraction as well as lesion fraction only
468 partially correlated to patients' disease status, in accordance with a large amount of
469 publications [36, 90]. This highlights the lack of specificity and sensitivity of volumetric
470 measurements, at least at the individual level.

471 It can appear odd that brain atrophy progresses in parallel to repair mechanisms, as suggested
472 by qMRI parameters. However, BPF reduction is minimal, and is not significant (see Table 3)
473 between T0 and T1. One should keep in mind that cortical atrophy is an irreversible
474 phenomenon. Given the inter- and intra-individual heterogeneity of MS progression, it is
475 possible that patients who have undergone neuron- axonal loss at some point in the disease
476 might be able to remyelinate their remaining axons, hopefully through therapeutic
477 intervention or lifestyle changes. Besides, axonal remyelination is not always effective. Here
478 we showed that variations in MTsat and R2* correlated to the disease activity status, but our
479 clinical evaluation based on EDSS is undoubtedly imprecise. Once again, the size and
480 heterogeneity of our cohort limits the interpretation of such results.

481 **Study limitation**

482 As mentioned here above, the small size and heterogeneous aspect of the present dataset
483 constitute major limitations of this study. Indeed, it is composed of only 17 patients, with a
484 rather broad range of characteristics such as age, disease duration, disease phenotype,
485 disease modifying treatment, etc., which are known to influence the disability state of the
486 patient and thus their ability to put together repair mechanisms within cerebral tissues [1, 75-
487 77, 91, 92]. In addition, the time interval between two scanning sessions varied rather widely

488 across patients (between 14 and 61 months), although it was brought back to an annual rate
489 where possible. All of these parameters were imposed by standard clinical follow up.
490 Therefore, these results should not be over-interpreted but are nevertheless promising and
491 call for a replication with a larger and more homogeneous or controlled set of MS patients.
492 Larger longitudinal studies are currently being held and will probably confirm these
493 preliminary results.

494 A second limitation is the absence of longitudinal MRI data acquired in a control group of
495 healthy subjects. However, we considered that literature of longitudinal studies of healthy
496 subjects that analysed tissue microstructure could constitute a solution for comparison with
497 MS patients. For example, in Bonnier et al. (2017) [68], the control group did not show any
498 significant differences regarding T1, T2* or MTR measurements over two years, and the
499 median age of their group is quite similar to ours (34,3 vs 36 years). Also, in Elkady et al. (2018)
500 [33], they found no longitudinal R2* effect in their control groups, even with an age range
501 superior to ours. Moreover, the median age of our population (< 60 years), as well as the
502 short period between two scanning sessions (median of 14 months), suggests that
503 microstructural alterations would not be noticeable in a healthy participants group, as many
504 quantitative ageing studies detected differences over much larger time periods [44, 70, 93].

505 **5. Conclusion**

506 These preliminary results highlight the relevance of multiple qMRI data in the monitoring of
507 MS disease, highlighting subtle changes within NABT and plaque dynamics in relation with
508 repair or disease progression. Of course, large scale longitudinal study would be needed to
509 reproduce these findings and better exploit the full potential of qMRI parameters.

510

511 **References**

512 [1] Lassmann, Hans. "Pathology and Disease Mechanisms in Different Stages of Multiple
513 Sclerosis." *Journal of the Neurological Sciences* 333, no. 1–2 (October 2013): 1–4.

514 <https://doi.org/10.1016/j.jns.2013.05.010>.

515

516 [2] Trapp, Bruce D., John Peterson, Richard M. Ransohoff, Richard Rudick, Sverre Mörk, and
517 Lars Bö. "Axonal Transection in the Lesions of Multiple Sclerosis." *New England Journal of*
518 *Medicine* 338, no. 5 (January 29, 1998): 278–85.

519 <https://doi.org/10.1056/NEJM199801293380502>.

520

521 [3] Haider, Lukas, Tobias Zrzavy, Simon Hametner, Romana Höftberger, Francesca Bagnato,
522 Günther Grabner, Siegfried Trattinig, Sabine Pfeifenbring, Wolfgang Brück, and Hans
523 Lassmann. "The Topography of Demyelination and Neurodegeneration in the Multiple Sclerosis
524 Brain." *Brain* 139, no. 3 (March 2016): 807–15. <https://doi.org/10.1093/brain/awv398>.

525

526 [4] Kutzelnigg, Alexandra, Claudia F. Lucchinetti, Christine Stadelmann, Wolfgang Brück,
527 Helmut Rauschka, Markus Bergmann, Manfred Schmidbauer, Joseph E. Parisi, and Hans
528 Lassmann. "Cortical Demyelination and Diffuse White Matter Injury in Multiple Sclerosis."
529 *Brain* 128, no. 11 (November 1, 2005): 2705–12. <https://doi.org/10.1093/brain/awh641>.

530

531 [5] Gh Popescu, Bogdan F, and Claudia F Lucchinetti. "Meningeal and Cortical Grey Matter
532 Pathology in Multiple Sclerosis." *BMC Neurology* 12, no. 1 (December 2012): 11.

533 <https://doi.org/10.1186/1471-2377-12-11>.

534

535 [6] Frischer, Josa M., Stephan Bramow, Assunta Dal-Bianco, Claudia F. Lucchinetti, Helmut
536 Rauschka, Manfred Schmidbauer, Henning Laursen, Per Soelberg Sorensen, and Hans
537 Lassmann. "The Relation between Inflammation and Neurodegeneration in Multiple Sclerosis
538 Brains." *Brain* 132, no. 5 (May 2009): 1175–89. <https://doi.org/10.1093/brain/awp070>.

539

540 [7] Brown, Robert A., Sridar Narayanan, and Douglas L. Arnold. "Imaging of Repeated Episodes
541 of Demyelination and Remyelination in Multiple Sclerosis." *NeuroImage: Clinical* 6 (2014): 20–
542 25. <https://doi.org/10.1016/j.nicl.2014.06.009>.

543

544 [8] Wang, Chenyu Tim, Michael Barnett, and Yael Barnett. "Imaging the Multiple Sclerosis
545 Lesion: Insights into Pathogenesis, Progression and Repair." *Current Opinion in Neurology* 32,
546 no. 3 (June 2019): 338–45. <https://doi.org/10.1097/WCO.0000000000000698>.

547

548 [9] Thompson, Alan J, Brenda L Banwell, Frederik Barkhof, William M Carroll, Timothy Coetzee,
549 Giancarlo Comi, Jorge Correale, et al. "Diagnosis of Multiple Sclerosis: 2017 Revisions of the
550 McDonald Criteria." *The Lancet Neurology* 17, no. 2 (February 2018): 162–73.
551 [https://doi.org/10.1016/S1474-4422\(17\)30470-2](https://doi.org/10.1016/S1474-4422(17)30470-2).

552

553 [10] Tabelow, Karsten, Evelyne Balteau, John Ashburner, Martina F. Callaghan, Bogdan
554 Draganski, Gunther Helms, Ferath Kherif, et al. "HMRI – A Toolbox for Quantitative MRI in
555 Neuroscience and Clinical Research." *NeuroImage* 194 (July 2019): 191–210.
556 <https://doi.org/10.1016/j.neuroimage.2019.01.029>.

557

- 558 [11] Schmierer, Klaus, Francesco Scaravilli, Daniel R. Altmann, Gareth J. Barker, and David H.
559 Miller. "Magnetization Transfer Ratio and Myelin in Postmortem Multiple Sclerosis Brain."
560 *Annals of Neurology* 56, no. 3 (September 2004): 407–15. <https://doi.org/10.1002/ana.20202>.
561
- 562 [12] Callaghan, Martina F., Gunther Helms, Antoine Lutti, Siawoosh Mohammadi, and Nikolaus
563 Weiskopf. "A General Linear Relaxometry Model of R_1 Using Imaging Data: General Linear
564 Relaxometry Model of R_1 ." *Magnetic Resonance in Medicine* 73, no. 3 (March 2015): 1309–
565 14. <https://doi.org/10.1002/mrm.25210>.
566
- 567 [13] Van Waesberghe, J. H. T. M., W. Kamphorst, C. J. A. De Groot, M. A. A. Van Walderveen,
568 J. A. Castelijns, R. Ravid, G. J. Lycklama a Nijeholt, et al. "Axonal Loss in Multiple Sclerosis
569 Lesions: Magnetic Resonance Imaging Insights into Substrates of Disability." *Annals of*
570 *Neurology* 46, no. 5 (November 1999): 747–54. [https://doi.org/10.1002/1531-
571 8249\(199911\)46:5<747::AID-ANA10>3.0.CO;2-4](https://doi.org/10.1002/1531-8249(199911)46:5<747::AID-ANA10>3.0.CO;2-4).
572
- 573 [14] Mottershead, J. P., K. Schmierer, M. Clemence, J. S. Thornton, F. Scaravilli, G. J. Barker, P.
574 S. Tofts, et al. "High Field MRI Correlates of Myelin Content and Axonal Density in Multiple
575 Sclerosis." *Journal of Neurology* 250, no. 11 (November 1, 2003): 1293–1301.
576 <https://doi.org/10.1007/s00415-003-0192-3>.
577
- 578 [15] Lema, Alfonso, Courtney Bishop, Omar Malik, Miriam Mattoscio, Rehiana Ali, Richard
579 Nicholas, Paolo A. Muraro, Paul M. Matthews, Adam D. Waldman, and Rexford D. Newbould.
580 "A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord

581 Microstructure in Multiple Sclerosis: MT of Brain and c-Spine in MS.” *Journal of Neuroimaging*
582 27, no. 2 (March 2017): 221–26. <https://doi.org/10.1111/ion.12377>.

583

584 [16] Helms, Gunther, Henning Dathe, and Peter Dechent. “Modeling the Influence of TR and
585 Excitation Flip Angle on the Magnetization Transfer Ratio (MTR) in Human Brain Obtained
586 from 3D Spoiled Gradient Echo MRI.” *Magnetic Resonance in Medicine* 64, no. 1 (July 2010):
587 177–85. <https://doi.org/10.1002/mrm.22379>.

588

589 [17] Bagnato, Francesca, Simon Hametner, Emma Boyd, Verena Endmayr, Yaping Shi, Vasiliki
590 Ikonomidou, Guanhua Chen, et al. “Untangling the R2* Contrast in Multiple Sclerosis: A
591 Combined MRI-Histology Study at 7.0 Tesla.” Edited by Quan Jiang. *PLOS ONE* 13, no. 3 (March
592 21, 2018): e0193839. <https://doi.org/10.1371/journal.pone.0193839>.

593

594 [18] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin
595 Haimburger, Christian Menard, et al. “The Influence of Brain Iron and Myelin on Magnetic
596 Susceptibility and Effective Transverse Relaxation - A Biochemical and Histological Validation
597 Study.” *NeuroImage* 179 (October 2018): 117–33.
598 <https://doi.org/10.1016/j.neuroimage.2018.06.007>.

599

600 [19] Stüber, Carsten, Markus Morawski, Andreas Schäfer, Christian Labadie, Miriam Wähnert,
601 Christoph Leuze, Markus Streicher, et al. “Myelin and Iron Concentration in the Human Brain:
602 A Quantitative Study of MRI Contrast.” *NeuroImage* 93 (June 2014): 95–106.
603 <https://doi.org/10.1016/j.neuroimage.2014.02.026>.

604

605 [20] Stankiewicz, James M., Mohit Neema, et Antonia Ceccarelli. « Iron and Multiple
606 Sclerosis ». *Neurobiology of Aging* 35 (September 2014): S51-58.
607 <https://doi.org/10.1016/j.neurobiolaging.2014.03.039>.

608

609 [21] Granziera, Cristina, Jens Wuerfel, Frederik Barkhof, Massimiliano Calabrese, Nicola De
610 Stefano, Christian Enzinger, Nikos Evangelou, et al. “Quantitative Magnetic Resonance
611 Imaging towards Clinical Application in Multiple Sclerosis.” *Brain* 144, no. 5 (June 22, 2021):
612 1296–1311. <https://doi.org/10.1093/brain/awab029>.

613

614 [22] Kolb, Hadar, Martina Absinta, Erin S. Beck, Seung-Kwon Ha, Yeajin Song, Gina Norato,
615 Irene Cortese, Pascal Sati, Govind Nair, and Daniel S. Reich. “7T MRI Differentiates
616 Remyelinated from Demyelinated Multiple Sclerosis Lesions.” *Annals of Neurology* 90, no. 4
617 (October 2021): 612–26. <https://doi.org/10.1002/ana.26194>.

618

619 [23] Edwards, Luke J., Evgeniya Kirilina, Siawoosh Mohammadi, and Nikolaus Weiskopf.
620 “Microstructural Imaging of Human Neocortex in Vivo.” *NeuroImage* 182 (November 2018):
621 184–206. <https://doi.org/10.1016/j.neuroimage.2018.02.055>.

622

623 [24] Lommers, Emilie, Jessica Simon, Gilles Reuter, Gaël Delrue, Dominique Dive, Christian
624 Degueldre, Evelyne Balteau, Christophe Phillips, and Pierre Maquet. “Multiparameter MRI
625 Quantification of Microstructural Tissue Alterations in Multiple Sclerosis.” *NeuroImage:
626 Clinical* 23 (2019): 101879. <https://doi.org/10.1016/j.nicl.2019.101879>.

627

628 [25] Lommers, Emilie, Camille Guillemain, Gilles Reuter, Eve Fouarge, Gaël Delrue, Fabienne
629 Collette, Christian Degueldre, Evelyne Balteau, Pierre Maquet, and Christophe Phillips. “VOXEL-
630 BASED Quantitative MRI Reveals Spatial Patterns of Grey Matter Alteration in Multiple
631 Sclerosis.” *Human Brain Mapping* 42, no. 4 (March 2021): 1003–12.
632 <https://doi.org/10.1002/hbm.25274>.

633
634 [26] Andica, Christina, Akifumi Hagiwara, Koji Kamagata, Kazumasa Yokoyama, Keigo Shimoji,
635 Asami Saito, Yuki Takenaka, et al. “Gray Matter Alterations in Early and Late Relapsing-
636 Remitting Multiple Sclerosis Evaluated with Synthetic Quantitative Magnetic Resonance
637 Imaging.” *Scientific Reports* 9, no. 1 (December 2019): 8147. [https://doi.org/10.1038/s41598-](https://doi.org/10.1038/s41598-019-44615-3)
638 [019-44615-3](https://doi.org/10.1038/s41598-019-44615-3).

639
640 [27] Bonnier, Guillaume, Alexis Roche, David Romascano, Samanta Simioni, Djalel Meskaldji,
641 David Rotzinger, Ying-Chia Lin, et al. “Advanced MRI Unravels the Nature of Tissue Alterations
642 in Early Multiple Sclerosis.” *Annals of Clinical and Translational Neurology* 1, no. 6 (June 2014):
643 423–32. <https://doi.org/10.1002/acn3.68>.

644
645 [28] Engström, Maria, Jan B. M. Warntjes, Anders Tisell, Anne-Marie Landtblom, and Peter
646 Lundberg. “Multi-Parametric Representation of Voxel-Based Quantitative Magnetic
647 Resonance Imaging.” Edited by Friedemann Paul. *PLoS ONE* 9, no. 11 (November 13, 2014):
648 e111688. <https://doi.org/10.1371/journal.pone.0111688>.

649
650 [29] Gracien, René-Maxime, Alina Jurcoane, Marlies Wagner, Sarah C. Reitz, Christoph Mayer,
651 Steffen Volz, Stephanie-Michelle Hof, et al. “Multimodal Quantitative MRI Assessment of

652 Cortical Damage in Relapsing-Remitting Multiple Sclerosis: Cortical Quantitative MRI in
653 RRMS." *Journal of Magnetic Resonance Imaging* 44, no. 6 (December 2016): 1600–1607.
654 <https://doi.org/10.1002/jmri.25297>.

655

656 [30] Neema, Mohit, James Stankiewicz, Ashish Arora, Venkata S.R. Dandamudi, Courtney E.
657 Batt, Zachary D. Guss, Ali Al-Sabbagh, and Rohit Bakshi. "T1- and T2-Based MRI Measures of
658 Diffuse Gray Matter and White Matter Damage in Patients with Multiple Sclerosis." *Journal of*
659 *Neuroimaging* 17 (April 2007): 16S-21S. <https://doi.org/10.1111/j.1552-6569.2007.00131.x>.

660

661 [31] Reitz, Sarah C., Stephanie-Michelle Hof, Vinzenz Fleischer, Alla Brodski, Adriane Gröger,
662 René-Maxime Gracien, Amgad Droby, et al. "Multi-Parametric Quantitative MRI of Normal
663 Appearing White Matter in Multiple Sclerosis, and the Effect of Disease Activity on T2." *Brain*
664 *Imaging and Behavior* 11, no. 3 (June 2017): 744–53. [https://doi.org/10.1007/s11682-016-](https://doi.org/10.1007/s11682-016-9550-5)
665 [9550-5](https://doi.org/10.1007/s11682-016-9550-5).

666

667 [32] Stevenson, V.L, G.J.M Parker, G.J Barker, K Birnie, P.S Tofts, D.H Miller, and A.J Thompson.
668 "Variations in T1 and T2 Relaxation Times of Normal Appearing White Matter and Lesions in
669 Multiple Sclerosis." *Journal of the Neurological Sciences* 178, no. 2 (September 2000): 81–87.
670 [https://doi.org/10.1016/S0022-510X\(00\)00339-7](https://doi.org/10.1016/S0022-510X(00)00339-7).

671

672 [33] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Gregg Blevins, and Alan H. Wilman.
673 "Discriminative Analysis of Regional Evolution of Iron and Myelin/Calcium in Deep Gray Matter
674 of Multiple Sclerosis and Healthy Subjects: Analysis of Iron and Myelin in MS." *Journal of*

675 *Magnetic Resonance Imaging* 48, no. 3 (September 2018): 652–68.
676 <https://doi.org/10.1002/jmri.26004>.

677

678 [34] Elkady, Ahmed M., Dana Cobzas, Hongfu Sun, Peter Seres, Gregg Blevins, and Alan H.
679 Wilman. “Five Year Iron Changes in Relapsing-Remitting Multiple Sclerosis Deep Gray Matter
680 Compared to Healthy Controls.” *Multiple Sclerosis and Related Disorders* 33 (August 2019):
681 107–15. <https://doi.org/10.1016/j.msard.2019.05.028>.

682

683 [35] Khalil, M., C. Langkammer, A. Pichler, D. Pinter, T. Gattringer, G. Bachmaier, S. Ropele, S.
684 Fuchs, C. Enzinger, and F. Fazekas. “Dynamics of Brain Iron Levels in Multiple Sclerosis: A
685 Longitudinal 3T MRI Study.” *Neurology* 84, no. 24 (June 16, 2015): 2396–2402.
686 <https://doi.org/10.1212/WNL.0000000000001679>.

687

688 [36] Gracien, René-Maxime, Sarah C. Reitz, Stephanie-Michelle Hof, Vinzenz Fleischer, Amgad
689 Droby, Mathias Wahl, Helmuth Steinmetz, Sergiu Groppa, Ralf Deichmann, and Johannes C.
690 Klein. “Longitudinal Quantitative MRI Assessment of Cortical Damage in Multiple Sclerosis: A
691 Pilot Study: Longitudinal Cortical QMRI in MS.” *Journal of Magnetic Resonance Imaging* 46,
692 no. 5 (November 2017): 1485–90. <https://doi.org/10.1002/jmri.25685>.

693

694 [37] Laule, Cornelia, I. M. Vavasour, K. P. Whittall, J. Oger, D. W. Paty, D. K. B. Li, A. L. MacKay,
695 and D. L. Arnold. “Evolution of Focal and Diffuse magnetisation Transfer Abnormalities in
696 Multiple Sclerosis.” *Journal of Neurology* 250, no. 8 (August 2003): 924–31.
697 <https://doi.org/10.1007/s00415-003-1115-z>.

698

699 [38] Hayton, T., J. Furby, K. J. Smith, D. R. Altmann, R. Brenner, J. Chataway, K. Hunter, D. J.
700 Tozer, D. H. Miller, and R. Kapoor. "Longitudinal Changes in Magnetisation Transfer Ratio in
701 Secondary Progressive Multiple Sclerosis: Data from a Randomised Placebo Controlled Trial of
702 Lamotrigine." *Journal of Neurology* 259, no. 3 (March 2012): 505–14.
703 <https://doi.org/10.1007/s00415-011-6212-9>.

704

705 [39] Dousset, Vincent, Annick Gayou, Bruno Brochet, and Jean-Marie Caille. "Early Structural
706 Changes in Acute MS Lesions Assessed by Serial Magnetization Transfer Studies." *Neurology*
707 51, no. 4 (October 1998): 1150–55. <https://doi.org/10.1212/WNL.51.4.1150>.

708

709 [40] Levesque, Ives R., Paul S. Giacomini, Sridar Narayanan, Luciana T. Ribeiro, John G. Sled,
710 Doug L. Arnold, and G. Bruce Pike. "Quantitative Magnetization Transfer and Myelin Water
711 Imaging of the Evolution of Acute Multiple Sclerosis Lesions: Quantitative MT and T₂ in Acute
712 MS Lesions." *Magnetic Resonance in Medicine* 63, no. 3 (March 2010): 633–40.
713 <https://doi.org/10.1002/mrm.22244>.

714

715 [41] Elskamp, Ij van den, DI Knol, H. Vrenken, G. Karas, A. Meijerman, M. Filippi, L. Kappos, et
716 al. "Lesional Magnetization Transfer Ratio: A Feasible Outcome for Remyelinating Treatment
717 Trials in Multiple Sclerosis." *Multiple Sclerosis Journal* 16, no. 6 (June 2010): 660–69.
718 <https://doi.org/10.1177/1352458510364630>.

719

720 [42] Filippi, Massimo, Maria A. Rocca, Gianvito Martino, Mark A. Horsfield, and Giancarlo
721 Comi. "Magnetization Transfer Changes in the Normal Appearing White Matter Precede the

722 Appearance of Enhancing Lesions in Patients with Multiple Sclerosis.” *Annals of Neurology* 43,
723 no. 6 (June 1998): 809–14. <https://doi.org/10.1002/ana.410430616>.

724

725 [43] Fazekas, F, S Ropele, C Enzinger, T Seifert, and S Strasser-Fuchs. “Quantitative
726 Magnetization Transfer Imaging of Pre-Lesional White-Matter Changes in Multiple Sclerosis.”
727 *Multiple Sclerosis Journal* 8, no. 6 (December 2002): 479–84.
728 <https://doi.org/10.1191/1352458502ms860oa>.

729

730 [44] Draganski, B., J. Ashburner, C. Hutton, F. Kherif, R.S.J. Frackowiak, G. Helms, and N.
731 Weiskopf. “Regional Specificity of MRI Contrast Parameter Changes in Normal Ageing
732 Revealed by Voxel-Based Quantification (VBQ).” *NeuroImage* 55, no. 4 (April 2011): 1423–34.
733 <https://doi.org/10.1016/j.neuroimage.2011.01.052>.

734

735 [45] Polman, Chris H., Stephen C. Reingold, Brenda Banwell, Michel Clanet, Jeffrey A. Cohen,
736 Massimo Filippi, Kazuo Fujihara, et al. “Diagnostic Criteria for Multiple Sclerosis: 2010
737 Revisions to the McDonald Criteria.” *Annals of Neurology* 69, no. 2 (February 2011): 292–302.
738 <https://doi.org/10.1002/ana.22366>.

739

740 [46] Guillemin, C., E. Lommers, G. Delrue, E. Gester, P. Maquet, et F. Collette. « The Complex
741 Interplay Between Trait Fatigue and Cognition in Multiple Sclerosis ». *Psychologica Belgica* 62,
742 n° 1 (March 2022): 108. <https://doi.org/10.5334/pb.1125>.

743

744

745 [47] Carey, Daniel, Francesco Caprini, Micah Allen, Antoine Lutti, Nikolaus Weiskopf, Geraint
746 Rees, Martina F. Callaghan, and Frederic Dick. "Quantitative MRI Provides Markers of Intra-,
747 Inter-Regional, and Age-Related Differences in Young Adult Cortical Microstructure."
748 *NeuroImage* 182 (November 2018): 429–40.
749 <https://doi.org/10.1016/j.neuroimage.2017.11.066>.

750

751 [48] Reuter, Gilles, Emilie Lommers, Evelyne Balteau, Jessica Simon, Christophe Phillips, Felix
752 Scholtes, Didier Martin, Arnaud Lombard, and Pierre Maquet. "Multiparameter Quantitative
753 Histological MRI Values in High-Grade Gliomas: A Potential Biomarker of Tumor Progression."
754 *Neuro-Oncology Practice* 7, no. 6 (December 4, 2020): 646–55.
755 <https://doi.org/10.1093/nop/npaa047>.

756

757 [49] Depierreux, Frédérique, Eric Parmentier, Laurane Mackels, Katherine Baquero, Christian
758 Degueldre, Evelyne Balteau, Eric Salmon, et al. "Parkinson's Disease Multimodal Imaging: F-
759 DOPA PET, Neuromelanin-Sensitive and Quantitative Iron-Sensitive MRI." *Npj Parkinson's*
760 *Disease* 7, no. 1 (December 2021): 57. <https://doi.org/10.1038/s41531-021-00199-2>.

761

762 [50] Nürnberger, Lucas, René-Maxime Gracien, Pavel Hok, Stephanie-Michelle Hof, Udo Rüb,
763 Helmuth Steinmetz, Rüdiger Hilker, Johannes C. Klein, Ralf Deichmann, and Simon Baudrexel.
764 "Longitudinal Changes of Cortical Microstructure in Parkinson's Disease Assessed with T1
765 Relaxometry." *NeuroImage: Clinical* 13 (2017): 405–14.
766 <https://doi.org/10.1016/j.nicl.2016.12.025>.

767

768 [51] Klein, J.C., M. Rolinski, L. Griffanti, K. Szewczyk-Krolikowski, F. Baig, C. Ruffmann, A.R.
769 Groves, R.A.L. Menke, M.T. Hu, and C. Mackay. "Cortical Structural Involvement and Cognitive
770 Dysfunction in Early Parkinson's Disease." *NMR in Biomedicine* 31, no. 4 (April 2018): e3900.
771 <https://doi.org/10.1002/nbm.3900>.

772

773 [52] Lutti, Antoine, Chloe Hutton, Jürgen Finsterbusch, Gunther Helms, and Nikolaus
774 Weiskopf. "Optimization and Validation of Methods for Mapping of the Radiofrequency
775 Transmit Field at 3T: Optimized RF Transmit Field Mapping at 3T." *Magnetic Resonance in*
776 *Medicine* 64, no. 1 (July 2010): 229–38. <https://doi.org/10.1002/mrm.22421>.

777

778 [53] Lutti, Antoine, Joerg Stadler, Oliver Josephs, Christian Windischberger, Oliver Speck,
779 Johannes Bernarding, Chloe Hutton, and Nikolaus Weiskopf. "Robust and Fast Whole Brain
780 Mapping of the RF Transmit Field B1 at 7T." Edited by Wang Zhan. *PLoS ONE* 7, no. 3 (March
781 12, 2012): e32379. <https://doi.org/10.1371/journal.pone.0032379>.

782

783 [54] Filippi, M., Rocca, M. A., Horsfield, M. A., Hametner, S., Geurts, J. J., Comi, G., & Lassmann,
784 H. "Imaging cortical damage and dysfunction in multiple sclerosis." *JAMA neurology*, 70(5)
785 (May 2013): 556–564. <https://doi.org/10.1001/jamaneurol.2013.1954>

786

787 [55] Hulst, Hanneke E, and Jeroen JG Geurts. "Gray Matter Imaging in Multiple Sclerosis: What
788 Have We Learned?" *BMC Neurology* 11, no. 1 (December 2011): 153.
789 <https://doi.org/10.1186/1471-2377-11-153>.

790

791

792 [56] Schmidt, Paul, Christian Gaser, Milan Arsic, Dorothea Buck, Annette Förchler, Achim
793 Berthele, Muna Hoshi, et al. "An Automated Tool for Detection of FLAIR-Hyperintense White-
794 Matter Lesions in Multiple Sclerosis." *NeuroImage* 59, no. 4 (February 2012): 3774–83.
795 <https://doi.org/10.1016/j.neuroimage.2011.11.032>.

796

797 [57] Weiskopf, Nikolaus, Martina F. Callaghan, Oliver Josephs, Antoine Lutti, and Siawoosh
798 Mohammadi. "Estimating the Apparent Transverse Relaxation Time ($R2^*$) from Images with
799 Different Contrasts (ESTATICS) Reduces Motion Artifacts." *Frontiers in Neuroscience* 8
800 (September 10, 2014). <https://doi.org/10.3389/fnins.2014.00278>.

801

802 [58] Preibisch, C., and R. Deichmann. "Influence of RF Spoiling on the Stability and Accuracy of
803 T_1 Mapping Based on Spoiled FLASH with Varying Flip Angles: Influence of RF Spoiling on T_1
804 Mapping." *Magnetic Resonance in Medicine* 61, no. 1 (January 2009): 125–35.
805 <https://doi.org/10.1002/mrm.21776>.

806

807 [59] Ashburner, John. "Symmetric Diffeomorphic Modeling of Longitudinal Structural MRI."
808 *Frontiers in Neuroscience* 6 (2013). <https://doi.org/10.3389/fnins.2012.00197>.

809

810 [60] Ashburner, John, and Karl J. Friston. "Unified Segmentation." *NeuroImage* 26, no. 3 (July
811 2005): 839–51. <https://doi.org/10.1016/j.neuroimage.2005.02.018>.

812

813 [61] Lorio, S., S. Fresard, S. Adaszewski, F. Kherif, R. Chowdhury, R.S. Frackowiak, J. Ashburner,
814 et al. "New Tissue Priors for Improved Automated Classification of Subcortical Brain Structures

815 on MRI.” *NeuroImage* 130 (April 2016): 157–66.
816 <https://doi.org/10.1016/j.neuroimage.2016.01.062>.

817

818 [62] Andersen, Sarah M., Steven Z. Rapcsak, and Pélégie M. Beeson. “Cost Function Masking
819 during Normalization of Brains with Focal Lesions: Still a Necessity?” *NeuroImage* 53, no. 1
820 (October 2010): 78–84. <https://doi.org/10.1016/j.neuroimage.2010.06.003>.

821

822 [63] Moon, Nathan, Elizabeth Bullitt, Koen van Leemput, and Guido Gerig. “Automatic Brain
823 and Tumor Segmentation.” In *Medical Image Computing and Computer-Assisted Intervention*
824 — *MICCAI 2002*, edited by Takeyoshi Dohi and Ron Kikinis, 2488:372–79. Lecture Notes in
825 Computer Science. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002.
826 https://doi.org/10.1007/3-540-45786-0_46.

827

828 [64] Pandit, Lekha. “No Evidence of Disease Activity (NEDA) in Multiple Sclerosis - Shifting the
829 Goal Posts.” *Annals of Indian Academy of Neurology* 22, no. 3 (2019): 261.
830 https://doi.org/10.4103/aian.AIAN_159_19.

831

832 [65] Anderson, Marti J. “Permutation Tests for Univariate or Multivariate Analysis of Variance
833 and Regression.” *Canadian Journal of Fisheries and Aquatic Sciences* 58, no. 3 (March 1, 2001):
834 626–39. <https://doi.org/10.1139/f01-004>.

835

836 [66] Yoav Benjamini and Yosef Hochberg. “Controlling the False Discovery Rate: a Practical and
837 Powerful Approach to Multiple Testing” *Journal of the Royal Statistical Society. Series B*
838 (*Methodological*), Vol. 57, No.1 (1995), 289-300.

839

840 [67] Leutritz, Tobias, Maryam Seif, Gunther Helms, Rebecca S Samson, Armin Curt, Patrick
841 Freund, and Nikolaus Weiskopf. "Multiparameter Mapping of Relaxation (R1 , R2 *), Proton
842 Density and Magnetization Transfer Saturation at 3 T: A Multicenter Dual-vendor
843 Reproducibility and Repeatability Study." *Human Brain Mapping* 41, no. 15 (October 15,
844 2020): 4232–47. <https://doi.org/10.1002/hbm.25122>.

845

846 [68] Bonnier, Guillaume, Benedicte Maréchal, Mário João Fartaria, Pavel Falkowskiy, José P.
847 Marques, Samanta Simioni, Myriam Schlupe, et al. "The Combined Quantification and
848 Interpretation of Multiple Quantitative Magnetic Resonance Imaging Metrics Enlightens
849 Longitudinal Changes Compatible with Brain Repair in Relapsing-Remitting Multiple Sclerosis
850 Patients." *Frontiers in Neurology* 8 (September 27, 2017): 506.
851 <https://doi.org/10.3389/fneur.2017.00506>.

852

853 [69] Rocca, Maria A, Giovanna Mastronardo, Mariemma Rodegher, Giancarlo Comi, and
854 Massimo Filippi. "Long-Term Changes of Magnetization Transfer-Derived Measures from
855 Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis," *AJNR Am J*
856 *Neuroradiol* 20 (1999):821–827

857

858 [70] Callaghan, Martina F., Patrick Freund, Bogdan Draganski, Elaine Anderson, Marinella
859 Cappelletti, Rumana Chowdhury, Joern Diedrichsen, et al. "Widespread Age-Related
860 Differences in the Human Brain Microstructure Revealed by Quantitative Magnetic Resonance
861 Imaging." *Neurobiology of Aging* 35, no. 8 (August 2014): 1862–72.
862 <https://doi.org/10.1016/j.neurobiolaging.2014.02.008>.

863

864 [71] Weiskopf, Nikolaus, Siawoosh Mohammadi, Antoine Lutti, and Martina F. Callaghan.
865 “Advances in MRI-Based Computational Neuroanatomy: From Morphometry to in-Vivo
866 Histology.” *Current Opinion in Neurology* 28, no. 4 (August 2015): 313–22.
867 <https://doi.org/10.1097/WCO.0000000000000222>.

868

869 [72] Hametner, Simon, Verena Endmayr, Andreas Deistung, Pilar Palmrich, Max Prihoda, Evelin
870 Haimburger, Christian Menard, et al. “The Influence of Brain Iron and Myelin on Magnetic
871 Susceptibility and Effective Transverse Relaxation - A Biochemical and Histological Validation
872 Study.” *NeuroImage* 179 (October 2018): 117–33.
873 <https://doi.org/10.1016/j.neuroimage.2018.06.007>.

874

875 [73] Mangeat, G., S.T. Govindarajan, C. Mainero, and J. Cohen-Adad. “Multivariate
876 Combination of Magnetization Transfer, T₂* and B₀ Orientation to Study the Myelo-
877 Architecture of the in Vivo Human Cortex.” *NeuroImage* 119 (October 2015): 89–102.
878 <https://doi.org/10.1016/j.neuroimage.2015.06.033>.

879

880 [74] Dutta, R., and B. D. Trapp. “Pathogenesis of Axonal and Neuronal Damage in Multiple
881 Sclerosis.” *Neurology* 68, no. Issue 22, Supplement 3 (May 29, 2007): S22–31.
882 <https://doi.org/10.1212/01.wnl.0000275229.13012.32>.

883

884 [75] Frischer, Josa M., Stephen D. Weigand, Yong Guo, Nilufer Kale, Joseph E. Parisi, Istvan
885 Pirko, Jay Mandrekar, et al. “Clinical and Pathological Insights into the Dynamic Nature of the

886 White Matter Multiple Sclerosis Plaque: Dynamic Nature of MS Plaque.” *Annals of Neurology*
887 78, no. 5 (November 2015): 710–21. <https://doi.org/10.1002/ana.24497>.

888

889 [76] Lassmann, Hans, Wolfgang Brück, and Claudia Lucchinetti. “Heterogeneity of Multiple
890 Sclerosis Pathogenesis: Implications for Diagnosis and Therapy.” *Trends in Molecular Medicine*
891 7, no. 3 (March 2001): 115–21. [https://doi.org/10.1016/S1471-4914\(00\)01909-2](https://doi.org/10.1016/S1471-4914(00)01909-2).

892

893 [77] Lucchinetti, Claudia, Wolfgang Brück, Joseph Parisi, Bernd Scheithauer, Moses Rodriguez,
894 and Hans Lassmann. “Heterogeneity of Multiple Sclerosis Lesions: Implications for the
895 Pathogenesis of Demyelination.” *Annals of Neurology* 47, no. 6 (June 2000): 707–17.
896 [https://doi.org/10.1002/1531-8249\(200006\)47:6<707::AID-ANA3>3.0.CO;2-Q](https://doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q).

897

898 [78] Zheng, Yufan, Jar-Chi Lee, Richard Rudick, and Elizabeth Fisher. “Long-Term
899 Magnetization Transfer Ratio Evolution in Multiple Sclerosis White Matter Lesions: Long-Term
900 MTR Evolution in MS WM Lesions.” *Journal of Neuroimaging* 28, no. 2 (March 2018): 191–98.
901 <https://doi.org/10.1111/jon.12480>.

902

903 [79] Chawla, Sanjeev, Ilya Kister, Tim Sinnecker, Jens Wuerfel, Jean-Christophe Brisset,
904 Friedemann Paul, and Yulin Ge. “Longitudinal Study of Multiple Sclerosis Lesions Using Ultra-
905 High Field (7T) Multiparametric MR Imaging.” Edited by Quan Jiang. *PLOS ONE* 13, no. 9
906 (September 13, 2018): e0202918. <https://doi.org/10.1371/journal.pone.0202918>.

907

908 [80] Lieury, Alice, Marie Chanal, Géraldine Androdias, Richard Reynolds, Sylvie Cavagna,
909 Pascale Giraudon, Christian Confavreux, and Serge Nataf. “Tissue Remodeling in Periplaque

910 Regions of Multiple Sclerosis Spinal Cord Lesions: Glia Remodeling in MS Spinal Cord.” *Glia* 62,
911 no. 10 (October 2014): 1645–58. <https://doi.org/10.1002/glia.22705>.

912

913 [81] Kuhlmann, Tanja, Samuel Ludwin, Alexandre Prat, Jack Antel, Wolfgang Brück, and Hans
914 Lassmann. “An Updated Histological Classification System for Multiple Sclerosis Lesions.” *Acta*
915 *Neuropathologica* 133, no. 1 (January 2017): 13–24. [https://doi.org/10.1007/s00401-016-](https://doi.org/10.1007/s00401-016-1653-y)
916 [1653-y](https://doi.org/10.1007/s00401-016-1653-y).

917

918 [82] Lassmann, Hans, Wolfgang Brück, and Claudia F. Lucchinetti. “The Immunopathology of
919 Multiple Sclerosis: An Overview.” *Brain Pathology* 17, no. 2 (April 2007): 210–18.
920 <https://doi.org/10.1111/j.1750-3639.2007.00064.x>.

921

922 [83] Hametner, Simon, Isabella Wimmer, Lukas Haider, Sabine Pfeifenbring, Wolfgang Brück,
923 and Hans Lassmann. “Iron and Neurodegeneration in the Multiple Sclerosis Brain.” *Annals of*
924 *Neurology* 74, no. 6 (December 2013): 848–61. <https://doi.org/10.1002/ana.23974>.

925

926 [84] Popescu, Bogdan F., Josa M. Frischer, Samuel M. Webb, Mylyne Tham, Reginald C. Adiele,
927 Christopher A. Robinson, Patrick D. Fitz-Gibbon, et al. “Pathogenic Implications of Distinct
928 Patterns of Iron and Zinc in Chronic MS Lesions.” *Acta Neuropathologica* 134, no. 1 (July 2017):
929 45–64. <https://doi.org/10.1007/s00401-017-1696-8>.

930

931 [85] De Stefano, N., A. Giorgio, M. Battaglini, M. Rovaris, M. P. Sormani, F. Barkhof, T.
932 Korteweg, et al. “Assessing Brain Atrophy Rates in a Large Population of Untreated Multiple

933 Sclerosis Subtypes.” *Neurology* 74, no. 23 (June 8, 2010): 1868–76.
934 <https://doi.org/10.1212/WNL.0b013e3181e24136>.

935

936 [86] Eshaghi, Arman, Ferran Prados, Wallace J. Brownlee, Daniel R. Altmann, Carmen Tur, M.
937 Jorge Cardoso, Floriana De Angelis, et al. “Deep Gray Matter Volume Loss Drives Disability
938 Worsening in Multiple Sclerosis: Deep Gray Matter Volume Loss.” *Annals of Neurology* 83, no.
939 2 (February 2018): 210–22. <https://doi.org/10.1002/ana.25145>.

940

941 [87] Bermel, Robert A, and Rohit Bakshi. “The Measurement and Clinical Relevance of Brain
942 Atrophy in Multiple Sclerosis.” *The Lancet Neurology* 5, no. 2 (February 2006): 158–70.
943 [https://doi.org/10.1016/S1474-4422\(06\)70349-0](https://doi.org/10.1016/S1474-4422(06)70349-0).

944

945 [88] Zivadinov, R., A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M.
946 G. Dwyer, E. M. Frohman, and O. Khan. “Mechanisms of Action of Disease-Modifying Agents
947 and Brain Volume Changes in Multiple Sclerosis.” *Neurology* 71, no. 2 (July 8, 2008): 136–44.
948 <https://doi.org/10.1212/01.wnl.0000316810.01120.05>.

949

950 [89] De Stefano, Nicola, Maria Laura Stromillo, Antonio Giorgio, Maria Letizia Bartolozzi,
951 Marco Battaglini, Mariella Baldini, Emilio Portaccio, Maria Pia Amato, and Maria Pia Sormani.
952 “Establishing Pathological Cut-Offs of Brain Atrophy Rates in Multiple Sclerosis.” *Journal of*
953 *Neurology, Neurosurgery & Psychiatry*, April 22, 2015, jnnp-2014-309903.
954 <https://doi.org/10.1136/jnnp-2014-309903>.

955

956 [90] Christian Enzinger, Frederik Barkhof, Olga Ciccarelli, Massimo Filippi, Ludwig Kappos,
957 Maria A. Rocca, et al. “Nonconventional MRI and Microstructural Cerebral Changes in Multiple
958 Sclerosis.” *Nature Reviews Neurology* 11, no. 12 (December 2015): 676–86.
959 <https://doi.org/10.1038/nrneurol.2015.194>.

960

961 [91] Bodini, Benedetta, Mattia Veronese, Daniel García-Lorenzo, Marco Battaglini, Emilie
962 Poirion, Audrey Chardain, Léorah Freeman, et al. “Dynamic Imaging of Individual
963 Remyelination Profiles in Multiple Sclerosis.” *Annals of Neurology* 79, no. 5 (May 2016): 726–
964 38. <https://doi.org/10.1002/ana.24620>.

965

966 [92] Patrikios, P., C. Stadelmann, A. Kutzelnigg, H. Rauschka, M. Schmidbauer, H. Laursen, P.
967 S. Sorensen, W. Bruck, C. Lucchinetti, and H. Lassmann. “Remyelination Is Extensive in a Subset
968 of Multiple Sclerosis Patients.” *Brain* 129, no. 12 (June 9, 2006): 3165–72.
969 <https://doi.org/10.1093/brain/awl217>.

970

971 [93] Gracien, RM., Nürnberger, L., Hok, P. *et al.* Evaluation of brain ageing: a quantitative
972 longitudinal MRI study over 7 years. *Eur Radiol* 27, 1568–1576 (2017).
973 <https://doi.org/10.1007/s00330-016-4485-1>

974

Tables

	<i>All Patients (n = 17)</i>	
<i>Age, y, median (range)</i>	36 (25-65)	
<i>Sex, F/M</i>	7/10	
<i>MS phenotype (RRMS/MS)</i>	11/6	
<i>Baseline disease duration, y, median (range)</i>	3.4 (0.3-28)	
<i>Baseline EDSS, median (range)</i>	2.5 (1-6.5)	
<i>Baseline number of relapses, median (range)</i>	RRMS: 2 (1-5)	PMS: N/A
<i>Disease-modifying treatment</i>	RRMS: First line, n: 5 Second line, n: 6	PMS: Ocrelizumab, n: 2 None, n: 4

976

977

Table 1: Demographic data of the study sample

978

	EDSS T0	EDSS T1/2	New lesion T1/2	Relapse T1/2	NEDA T1/2	EDSS T1	New lesion T1	Relapse T1	NEDA T1	Time period T0-T1	Score
sub-001	2	2	None	None	YES	2	None	None	YES	30	1
sub-002	1.5	1.5	None	None	YES	1.5	None	None	YES	27	1
sub-003	2	2	None	None	YES	2	None	None	YES	27	1
sub-004	3	3	None	None	YES	3.5	None	None	YES	25	1
sub-005	1	1	None	None	YES	1	None	None	YES	24	1
sub-006	1.5	1.5	None	None	YES	1.5	None	None	YES	24	1
sub-007	2	2	None	None	YES	2	None	None	YES	22	1
sub-008	3.5	4.5	None	N/A	NO	5	None	N/A	NO	51	0
sub-009	2	2.5	None	None	YES	2.5	None	None	YES	57	1
sub-010	6	6	Yes	N/A	NO	6.5	None	None	NO	14	0
sub-011	6	6	None	N/A	YES	6.5	None	N/A	NO	14	1
sub-012	1	1.5	None	None	YES	1.5	None	None	YES	55	1
sub-013	5.5	6	None	N/A	NO	6.5	None	N/A	NO	60	0
sub-014	2.5	3.5	Yes	Yes	NO	3	None	None	YES	57	1
sub-015	4	4.5	None	N/A	NO	5	None	N/A	NO	51	0
sub-016	5	4.5	Yes	N/A	NO	4.5	None	N/A	YES	61	1
sub-017	2	3	Yes	Yes	NO	3	Yes	Yes	NO	56	0

980

981

982

983

Table 2: Longitudinal clinical information and derived disease status score. The time period between T0 and T1 is expressed in months.

	NAWM	NACGM	NADGM
MTsat	0.039 (.011)*	0.017 (.007)*	0.004 (.749)
PD	-0.018 (.670)	0.405 (.225)	0.250 (.552)
R1	0.009 (.139)	0.004 (.471)	0.010 (.111)
R2*	0.295 (.002)*	0.121 (.092)	0.066 (.770)
BPF	-0.884 (.1562)		
LF	21.23 (.1082)		

984

985

986

987

988

Table 3: Regression coefficients and their associated p -values (in parentheses) for the effects of X_{status} on the individual ARoC for each qMRI parameter (MTsat, PD, R1 and R2*) and for volumetric measurements (BPF and LF).

* Results significant at $p < .05$, FDR corrected.

989

990 **Legends of figures**

991

992 **Figure 1:** Chartflow of data creation and processing (see text). MPM maps were created with
993 the hMRI-toolbox, FLAIR images were directly acquired for both sessions (T0 and T1). A
994 preliminary mask was constructed based on T0 FLAIR. All images (MPM and FLAIR, T0 and
995 T1) were co-registered to the MPM T0 space. Segmentation using USwL allowed to isolate
996 the different tissue classes.

997

998 **Figure 2:** Schematic illustration of the NAWM and 3 lesions-related areas: focal FLAIR lesion
999 (dark gray area), initial peripheral lesion detected at T0 (medium gray area), later peripheral
1000 lesion detected at T1 (dashed, left, and light gray, right, area).

1001

1002 **Figure 3:** Line plots illustrating individual ARoC's for MTsat (left) and R2* (right) in NAWM.
1003 Each line corresponds to one subject. Dotted lines represent increasing rates.

1004

1005 **Figure 4:** Violin plots of significant change rates in microstructure with respect to X_{status} .
1006 From left to right: MTsat in NAWM, MTsat in NACGM, R2* in NAWM. * $P < .05$.

1007

1008 **Figure 5:** Microstructural parameters in NAWM and the 3 lesion-related areas, for each scanning time
1009 T0 and T1. P-values were obtained with *post-hoc* tests on the tissue area effect. * $P < .05$.

1010

1011

1012 **Appendix A: Supplementary data legends**

1013 **Supplementary data 1:** Multi-echo 3D FLASH acquisition parameters for Siemens Magnetom
1014 PRISMA MRI

1015

1016 **Supplementary data 2:** Extended demographic data. Age, disease duration, EDSS and
1017 relapses values were taken at baseline.

1018

1019 **Supplementary data 3:** Additional follow-up clinical data for each subject.

1020

1021 **Supplementary data 4:** Line plots illustrating individual ARoC's for PD (left) and R1 (right) in
1022 NAWM. Each line corresponds to one subject. Dotted lines represent increasing rates.

1023

1024 **Supplementary data 5:** Differences of lesion class Least Squares Means. First two columns
1025 correspond to tissue class labels (0 = NAWM, 1 = Later peripheral lesion, 2 = Initial peripheral
1026 lesion, 3 = FLAIR lesion).

1027

1028

1029




Figure 1: Chartflow of data creation and processing (see text). MPM maps were created with the hMRI-toolbox, FLAIR images were directly acquired for both sessions (T0 and T1). A preliminary mask was constructed based on T0 FLAIR. All images (MPM and FLAIR, T0 and T1) were co-registered to the MPM T0 space. Segmentation using USwL allowed to isolate the different tissue classes.




Figure 2: Schematic illustration of the NAWM and 3 lesions-related areas: focal FLAIR lesion (dark gray area), initial peripheral lesion detected at T₀ (medium gray area), later peripheral lesion detected at T₁ (dashed, left, and light gray, right, area)




Figure 3: Line plots illustrating individual AROCs for MTsat (left) and R2* (right) in NAWM.

Each line corresponds to one subject. Dotted lines represent increasing rates.






Figure 4: Violin plots of significant change rates in microstructure with respect to X_{status} .

From left to right: MTsat in NAWM, MTsat in NACGM, R2* in NAWM. * $P < .05$.


MTsat



PD



R1



R2*




Figure 5: Microstructural parameters in NAWM and the 3 lesion-related areas, for each scanning time T0 and T1. P-values were obtained with *post-hoc* tests on the tissue area effect. * $P < .05$.